OBJECTIVES: Deep brain stimulation (DBS) and dopaminergic medication effectively alleviate the motor symptoms in Parkinson's disease (PD) patients, but their effects on the sensory symptoms of PD are still not well understood. To explore early somatosensory processing in PD, we recorded magnetoencephalography (MEG) from thirteen DBS-treated PD patients and ten healthy controls during median nerve stimulation. METHODS: PD patients were measured during DBS-treated, untreated and dopaminergic-medicated states. We focused on early cortical somatosensory processing as indexed by N20m, induced gamma augmentation (31-45Hz and 55-100Hz) and induced beta suppression (13-30Hz). PD patients' motor symptoms were assessed by UPDRS-III. RESULTS: Using Bayesian statistics, we found positive evidence for differentiated effects of treatments on the induced gamma augmentation (31-45Hz) with highest gamma in the dopaminergic-medicated state and lowest in the DBS-treated and untreated states. In contrast, UPDRS-III scores showed beneficial effects of both DBS and dopaminergic medication on the patients' motor symptoms. Furthermore, treatments did not affect the amplitude of N20m. CONCLUSIONS: Our results suggest differentiated effects of DBS and dopaminergic medication on cortical somatosensory processing in PD patients despite consistent ameliorating effects of both treatments on PD motor symptoms. SIGNIFICANCE: The differentiated effect suggests differences in the effect mechanisms of the two treatments.
Antiparkinson Agents/therapeutic use , Deep Brain Stimulation/methods , Evoked Potentials, Somatosensory/physiology , Magnetoencephalography/methods , Parkinson Disease/physiopathology , Somatosensory Cortex/physiopathology , Antiparkinson Agents/pharmacology , Evoked Potentials, Somatosensory/drug effects , Female , Humans , Magnetoencephalography/drug effects , Male , Middle Aged , Parkinson Disease/therapy , Somatosensory Cortex/drug effects
